Business
Allogene Therapeutics Reports Second Quarter 2021 Financial Results
CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgkin LymphomaNext CD19 Program Clinical Update Planned for Q4 2021ALLO-501A Pivotal Trial on Track for Initiation in Late 2021 BCMA Program Highlights Updated Phase 1 UNIVERSAL Data on ALLO-715 Planned for Q4 2021Began Dosing Patients in Phase 1 IGNITE Trial of ALLO-605, the First TurboCAR™ T Cell Therapy, for Relapsed/Refractory Multiple MyelomaALLO-605 Granted Fast Track Designation by the FDA Solid Tumor Program Highlights Phase 1 TRAVERSE Trial Ongoing for ALLO-316 (anti-CD70) in Advanced or Metastatic Renal Cell Carcinoma. Initial Clinical Readout Expected in 2022 Corporate Highlights Appointed Liz Barrett and Vicki Sato, Ph.D., Executives with Significant Strategic and Commercial Expertise, to the Board of DirectorsState-of-the-Art cGMP Manufacturing Facility in Newark, California to Support Industry’s First Allogeneic Pivotal Trial and Future Commercial LaunchEnded Second Quarter with $913 Million in Cash, Cash Equivalents and Investments Quarterly Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported second quarter 2021 financial results for the quarter ended June 30, 2021. “We have made exceptional progress across our broad pipeline of AlloCAR T candidates, bringing our goal of revolutionizing cell therapy for patients with blood cancers and solid tumors closer to reality,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Our foundational and ongoing work has the potential to drive us toward an industry first - our planned pivotal trial for ALLO-501A in relapsed/refractory non-Hodgkin lymphoma which we expect to initiate at the end of this year. This month, we are also marking an exciting milestone with the planned inauguration of our state-of-the-art manufacturing facility, Cell Forge 1. This facility is intended to allow us to...